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Crystallized but not soluble uric 
acid elicits pro-inflammatory 
response in short-term whole blood 
cultures from healthy men
Henrik Brovold1, trine Lund2, Dmitri svistounov1,3, Marit D. solbu1,3, trond G. Jenssen1,6, 
Kirsti Ytrehus2 & svetlana N. Zykova1,4,5
Several epidemiological studies have pointed at serum uric acid (SUA) as an independent risk factor for 
mortality, diabetes, hypertension, cardiovascular and kidney disease; however, no clear pathogenic 
pathway is established. Uric acid (UA) crystals show pro-inflammatory properties and can thus create or 
contribute to the state of chronic low-grade inflammation, a widely accepted pathogenic mechanism in 
several of the above-mentioned pathologies. On the other hand, soluble uric acid possesses antioxidant 
properties that might attenuate inflammatory responses. We aimed to explore the net effects of 
experimentally rising SUA in human whole blood cultures on several mediators of inflammation. 
production of tNF-α, IL-1ß, IL-1RA, MCP-1 and IL-8 was assessed upon addition of 200 µM UA, 500 µM 
UA or monosodium urate (MSU) crystals in the presence or absence of 5 ng/ml lipopolysaccharide (LPS). 
RT-qPCR and multiplex bead based immunoassay were used to measure mRNA expression and cytokine 
release at 2 and 4 h of culture, respectively. 14C labeled UA was used to assess intracellular uptake of 
UA. We show that crystallized, but not soluble, UA induces production of pro-inflammatory mediators 
in human whole blood. Soluble UA is internalized in blood cells but does not potentiate or reduce LPS-
induced release of cytokines.
Hyperuricemia is a modifiable condition that can lead to gout, and may be an independent risk factor for mortal-
ity1, renal disease2,3, cardiovascular events4–7, cancer8,9, hypertension10,11, and diabetes12. Hyperuricemia is also a 
common problem after renal, liver and cardiac transplantation13.
Epidemiological studies are conflicting whether elevated serum uric acid (SUA) is an independent risk factor 
for cardiovascular disease. Some studies have found SUA to be an independent cardiovascular risk factor1,4,5,7,14, 
but others did not15–18.
In humans, the concentration of uric acid (UA) can reach its theoretical supersaturation threshold in extra-
cellular fluids. This is due to multiple missense mutations in the uricase enzyme responsible for degrading UA to 
a more soluble allantoin in most other species. Precipitation of uric acid into monosodium urate (MSU) crystals 
in joints elicits acute aseptic inflammation, the gouty arthritis, prevalence of which increases with increasing SUA 
levels19. Deposition of MSU crystals can also occur in other tissues and organs in humans, although it is reported 
seldom20–22. Formation of MSU crystals may also occur in the blood from hyperuricemic patients22.
MSU crystals have recently been suggested as a damage associated molecular pattern (DAMP) which stim-
ulates both the innate and adaptive immune system23–25. However, the loss of functional uricase and increase 
in SUA might represent an evolutionary benefit for humans. UA is recognized to be a major antioxidant in 
human plasma26 and some studies have suggested a neuroprotective effect27–29. UA´s potential physiological role 
is further supported by the high rate of reabsorption of filtered UA in the kidneys25,30. Soluble UA has been 
shown to have both antioxidative and pro-oxidative properties in different animal and in vitro experimental 
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models31. Anti-inflammatory effects have also been reported for other antioxidants added to lipopolysaccha-
ride (LPS)-stimulated whole blood cultures32,33. One doctoral thesis reported that UA attenuated inflammatory 
responses to LPS indirectly by inhibiting the release of pro-inflammatory cytokines TNF-α and IL-1ß in a human 
monocyte culture, this effect, however, could not be attributed to antioxidant properties of UA34. Little is known 
with respect to the direct effect of elevated SUA on inflammatory markers in blood. Therefore, we aimed to inves-
tigate whether short-term exposure of blood cells to high concentration of UA elicit a pro-inflammatory response 
or compromise cell viability, either directly or through precipitation into MSU crystals. Alternatively, UA might 
elicit protective effects in blood cells exposed to inflammatory stimuli. We also examined to what extent UA is 
internalized by blood cells.
Results
Soluble UA and blood cell viability. Measurements made in blood cultures at 15 minutes (baseline) 
and 1 h 45 min of incubation showed that pH did not significantly change during incubation (pH 7.46 ± 0.04 
vs. 7.44 ± 0.07 respectively, n = 6, paired t-test, p = 0.3). At the start of incubation, the mean pH in the whole 
blood cultures was at the upper limit of the reference range of physiological pH for arterial blood (7.35–7.45). As 
expected, glucose concentration was significantly lower, while lactate concentration was significantly higher at 
the end of the incubation at 1 h 45 minutes (Fig. 1A–C). There were no significant differences in pH between the 
cultures exposed to vehicle only and cultures exposed to LPS, after 3 h 45 minutes incubation (pH 7.41 ± 0.02 and 
pH 7.42 ± 0.03, n = 7, paired t-test, p = 0.2). Vehicle treated cultures had higher glucose concentration at the end 
of the incubation compared to LPS-treated cells (2.0 ± 0.6 mM vs 1.5 ± 0.6 mM, respectively, n = 7, paired t-test 
p < 0.0001). Lactate concentration was lower in the vehicle-treated cultures vs LPS (6.0 ± 0.3 mM vs 6.8 ± 0.3 mM 
respectively, n = 7, paired t-test p < 0.0001) (Fig. 2A–C). Hematological differential cell counts were used as a 
measure of cell viability in the whole blood cultures. There were no significant differences in the total white 
blood cell (WBC) count in cultures exposed to 200 µM UA, 500 µM UA or MSU crystals for 2 h compared to 
vehicle-treated controls (4.3 ± 0.9 109/L, 4.3 ± 1.0 109/L, 4.3 ± 0.9 109/L vs 4.4 ± 1.0 109/L respectively, n = 10) 
(Fig. 3A). As shown in Fig. 3B, no statistically significant decreases in the total WBC count was observed when 
whole blood cultures were exposed to 500 µM UA (4.4 ± 0.6 109/L), LPS (4.1 ± 0.6 109/L) or LPS + UA (4.2 ± 0.6 
109/L) for 4 h compared to vehicle (4.3 ± 0.6 109/L, adj. p = 0.55, 0.07 and 0.62 respectively, n = 4). When the 
baseline vehicle sample was compared against vehicle incubated for 4 h, there was a significant decrease in WBC´s 
(4.9 ± 0.4 109/L vs 4.3 ± 0.6 109/L, p = 0.04, n = 4).
Figure 1. Metabolic parameters in whole blood suspension cultures exposed to vehicle (0.9% NaCl) for 
15 minutes (baseline) or for 1 hour 45 minutes (end of culture). The results are paired samples, n = 6 in 
both groups. The bars and whiskers represent mean + SD (A) pH (B) Glucose (C) Lactate. ***p < 0.001, 
****p < 0.0001.
Figure 2. Metabolic parameters in whole blood suspension cultures exposed to vehicle (0.9% NaCl) or 
lipopolysaccharide (LPS, 5 ng/ml) for 3 h 45 min. The results are paired samples, n = 7 in both groups. The 
bars and whiskers represents the mean + SD. (A) pH (B) Glucose concentration (C) Lactate concentration. 
****p < 0.0001.
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Cytokine production in whole blood cultures exposed to soluble UA or MSU crystals. No sig-
nificant changes in protein concentration of TNF-α, Il-1ß, MCP-1, IL-8 and Il-1RA were observed following 
exposure of blood cultures to increasing concentrations of soluble UA for 4 h (Fig. 4A–E). At the same time, 
MSU crystals induced significant release of TNF-α, borderline significant release of MCP-1, and clearly elevated 
releases of IL-8 and IL-1RA (95% CI of difference from vehicle only exposed controls: 5–724 fg/ml, p adj = 0.047; 
−7–524 fg/ml, p adj = 0.056; 1008–2092 fg/ml, p adj = 0.0002; 2743–6741 fg/ml, p adj = 0.0005 respectively, 
n = 8). There were no statistically significant differences between the cultures in IL-1ß concentrations due to wide 
variation of values. ICAM-1, which expression - as expected - did not change in the course of the experiment, was 
used as a control.
In order to differentiate between the release of pre-formed cytokines from their de-novo production, expres-
sion of TNF-α, IL-1ß, MCP-1, IL-8 and Il-1RA mRNA was assessed with qPCR. As illustrated in Fig. 4G–K, 
addition of 200 µM or 500 µM of soluble UA to whole blood cultures on top of the donors’ natural serum UA level 
had no significant effect on the cytokines mRNA expression after two hours incubation. At the same time, MSU 
crystals caused a significant increase in IL-8 and IL-1RA mRNA expression (95% CI of difference from the vehi-
cle: 1.15–3.39, p adj = 0.0014 and 0.38–1.38, p adj = 0.0031 respectively, n = 8). No significant effect of exposure 
to MSU crystals was observed on TNF-α, IL-1ß and MCP-1 mRNA.
Effect of soluble UA on LPS-stimulated production of cytokines in whole blood cultures. To 
investigate the potential effect of UA as an antioxidant able to counteract pathogen-induced cytokine and 
chemokine production, LPS-stimulated production of TNF-α, Il-1ß, MCP-1, IL-8 and Il-1RA was studied in 
whole blood cultures pre-exposed to vehicle or increasing concentrations of soluble UA for 1 hour in vitro. After 
4 h of incubation, LPS caused significant release of all the studied cytokines but neither 200 µM or 500 µM UA 
modulated LPS-responses (Fig. 5A–E). Similarly, LPS-induced increase in the cytokines mRNA expression meas-
ured at 2 h was not attenuated by pre-exposure of cultures to either 200 µM or 500 µM UA (Fig. 5G–K).
Internalization of UA by blood cells. In order to study whether blood cells can internalize UA, whole 
blood cultures were exposed to high concentration of UA with trace amounts (1‰) of 14C-labelled UA, and the 
radioactivity distribution between plasma and cellular fractions was compared at various time points. The results 
indicated that cell-associated radioactivity rose rapidly but the uptake process reached equilibrium after 2 h with 
approximately 17% and 14% of added radioactivity being internalized in male and female groups respectively 
(Fig. 6). Whereas, overall UA uptake were numerically lower in the female group compared to male (p value 
0.0151), the differences in the rate of uptake are minor and not significant (rate constant K 1.409, SE 0.3635 for 
males and K 1.133, SE 0.1799 for females (p value 0.5002)).
Humans lack the UA-degrading enzyme uricase. However, UA can still be degraded by non-specific oxidation. 
We did not detect any sign of UA degradation in the blood culture supernatants during 4 hours of incubation 
(data not shown). The uptake of UA was unaffected by the presence of LPS (5 ng/ml) in the blood cultures, either 
when added simultaneously or following 1 h of pre-incubation with UA (data now shown). Addition of trans-
porter inhibitors probenecid and tranilast to blood cultures failed to decrease the level of cell-associated radioac-
tivity or the rate of internalization of radiolabeled UA.
Figure 3. Absolute number of WBC in whole blood suspension cultures subjected to (A) 2- hour incubation 
with vehicle (0.9% NaCl), 200 µM uric acid (UA), 500 µM UA or monosodium urate (MSU) crystals, n = 10; 
or to (B) 4h-incubation with 500 µM UA or vehicle in the presence or absence of 5 ng/ml lipopolysaccharide 
(LPS) compared to baseline, n = 4. The results are paired samples. The bars and whiskers represents mean + SD. 
*p ≤ 0.05, **p < 0.001, ****p < 0.0001.
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Discussion
Addition of soluble UA to whole blood cultures from healthy male volunteers did not illicit an acute 
pro-inflammatory response or modulate LPS induced stimulation as judged by unchanged plasma concentra-
tion of TNF-α, IL-1ß, IL-1RA, MCP-1 and IL-8. This also applied to UA added in supranormal concentrations. 
Figure 4. Plasma concentration of TNF-α (A), IL-1β (B), MCP-1 (C), IL-8 (D), IL-1RA (E), ICAM-1(F) 
and mRNA levels for TNF-α (G), IL-1β (H), MCP-1 (I), IL-8 (J), IL-1RA (K) normalized to house keeping 
gene RPL13A (L) in whole blood cultures exposed to vehicle (control), 200 µM uric acid (UA), 500 µM UA 
or monosodium urate (MSU) crystals. The blood was cultured in the presence of uric acid for 3 h for gene 
expression study and for 5 h for measurement of cytokines. The bars are mean + SD. N = 8 individual donors. 
#p = 0.055; *p < 0.05; **p < 0.01; ***p < 0.001.
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Similarly, the gene expression analysis showed no effect of soluble UA on TNF-α, IL-1ß, IL-1RA, MCP-1 and IL-8 
mRNA expression in the cultures. Results from the UA uptake experiment show that UA is internalized by blood 
cells when added ex vivo to whole blood.
Figure 5. Plasma concentration of TNF-α (A), IL-1β (B), MCP-1 (C), IL-8 (D), IL-1RA (E), ICAM-1(F) and 
mRNA levels for TNF-α (G), IL-1β (H), MCP-1 (I), IL-8 (J), IL-1RA (K) normalized to house keeping gene 
RPL13A (L) in whole blood cultures exposed to vehicle (control), 200 µM uric acid (UA) or 500 µM UA and 
stimulated with LPS (5 ng/ml). Cultures pre-exposed to uric acid for 1 hour were incubated with LPS for 2 h for 
gene expression study and for 4 hours for measurements of cytokines. The bars are mean + SD. N = 8 individual 
donors. Cytokine levels were measured in culture plasma with multiplex luminescence immunoassay.
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Our results are in line with a similar study which showed no pro- or anti-inflammatory effects of supraphysi-
ological concentrations of soluble UA on human whole blood35. With regards to the pro-inflammatory properties 
of soluble uric acid in other species, the reports in the literature are somewhat different. Although not being 
pro-inflammatory per se, uric acid was convincingly reported to have adjuvant properties as it stimulated expres-
sion of co-stimulatory molecules CD86 and CD80 on dendritic cells but did not affect their rate of phagocytosis 
of particulate antigens. Of note, the concentrations of uric acid that up-regulated co-stimulatory molecules were 
very close to concentrations at which crystal formation occurs, at least in humans23. Another study found that 
soluble uric acid was able to induce IL-1ß release followed by production of mitochondrial ROS and caspase 1 
activation36. Both studies used bone-marrow derived in vitro maturated macrophages from rodents. Rodents have 
considerably lower uric acid levels in vivo due to presence of functional uricase gene, and the rise in uric acid that 
macrophages became exposed to in vitro (from an assumed baseline of 13 μΜ37 to 900 μΜ) was relatively higher 
than concentration delta in our model (from an assumed baseline of 300 μΜ to 500–800 μΜ). Moreover, in the 
study by Braga et al.36 the dose-dependent increase in IL-1ß production in response to soluble uric acid was only 
observed in the presence of LPS in cultures of rodent macrophages, and no signs of activation were detected in 
human cells. These results therefore were completely in line with our data.
Addition of soluble UA to LPS-stimulated blood did not have any attenuating effect on the elicited 
pro-inflammatory response as could be expected from antioxidant properties of UA. Earlier studies in whole 
blood ex vivo have shown that the main chemotactic factors for monocytes and neutrophils, MCP-1 and IL-8 
respectively, are regulated by reactive oxygen species (ROS). Adding the exogenous oxygen radical scavengers - 
N-acetyl cysteine and dimetyl sulfoxide - to LPS-stimulated whole blood, was reported to reduce the release of 
MCP-1 and IL-832,33. However, a study in monocytes found UA to attenuate the LPS-induced release of cytokines 
TNF-α and IL-1ß without affecting intracellular ROS, which suggests that the effect might have been mediated 
by other than antioxidant properties of UA34. Due to the natural levels of UA in whole blood from healthy males, 
isolated monocytes in culture might be a more suitable model to study the potential effect of UA as a molecule 
with immune-regulatory properties. If UA has immune-regulatory properties, normal SUA levels of healthy indi-
viduals might be sufficient for this to occur and there is no additional gain of further increasing UA ex vivo.
Nevertheless, addition of crystallized UA to our whole blood cultures caused significant upregulation of 
mRNA and protein release of several pro-inflammatory cytokines, particularly chemokine IL-8 and IL-1RA. 
These results contrast a lack of stimulatory effect of soluble UA.
Uric acid is an end product of purine degradation pathway, and an acute rise of serum uric acid in the cir-
culation takes place in situations with massive cell death and break-down of nucleic acids. It is logical that such 
a sign would be perceived by the immune system as a danger signal. Indeed, high serum uric acid is a pre-
dictor of adverse events as it is longitudinally associated with increased mortality and morbidity1–12. It is now 
well established that uric acid crystals are recognized as endogenous danger-associated molecular patterns23,38,39. 
MSU-crystal represents a repetitive purine structure that is likely to be sensed as foreign polynucleotide-like 
molecule by the cells of immune system. The ability of MSU-crystals to activate pro-inflammatory pathways in 
phagocytes is linked to engagement of specific receptors40–44, membrane rearrangements45 and complement acti-
vation46. Accordingly, lack of sufficient expression or engagement of such receptors as CD14, TLR-2 and −4 and 
Fc-receptors, for example due to immaturity of phagocytes, insufficient opsonization or blockage of binding sites 
on MSU-crystals would all prevent an inflammatory response from full activation.
Soluble uric acid as opposed to its crystals is a rather small molecule and its size would prevent it from 
cross-linking stimulatory receptors on the surface of phagocytes or opsonization. From the evolutionary per-
spective, it is interesting that in humans, acute elevation of uric acid in its soluble form is not a pro-inflammatory 
stimulus but crystals are, yet both forms have the same origin and indicate cell death and danger. One possible but 
speculative explanation is a dialectical transition of quantity into quality where solubility of uric acid indicates 
Figure 6. Uptake of 14C-labelled UA in whole blood suspension cultures from healthy volunteers. Freshly 
drawn blood was mixed in equal volumes with RPMI-1640 containing 1000 µM UA and 1 µM 14C-labelled UA 
and incubated at 37 °C 5% CO2 for 0, 0.5, 1, 2 and 4 h. Circles – males (n = 3), squares – females (n = 3), data are 
mean ± SD.
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that a critical threshold in the number of dead cells is not reached yet, but further rise resulting in formation of 
crystals, becomes a sign of considerable cellular catastrophe. Crystallization indeed can be augmented by addi-
tional danger signals present in necrotic tissues, such as changes in pH, temperature and ion concentrations, or 
presence of immunoglobulins47–53. Indeed, a surprisingly small proportion of people with hyperuricemia experi-
ence MSU crystal deposition disease, suggesting either subclinical disease, or that additional factors are needed 
for MSU crystal formation in human tissue. The conditions in our model with relatively good cell viability (Fig. 3) 
might therefore not be fully suitable to study the effects of in vivo crystallized UA as a DAMP23,54.
NLRP3 induced IL-1ß production has been previously implicated as a key element in crystal-elicited 
pro-inflammatory response55. Contrary to this study and several other reports we could not demonstrate signifi-
cant up-regulation of IL-1ß in response to MSU crystals. We believe this discrepancy is related to the fact that in 
our model MSU crystals interact with peripheral blood mononuclear cells (PBMC) suspended in plasma and not 
with adherent maturated macrophages. It has been shown that silica aluminum salt crystals did not induce IL-1β 
release in human PBMCs unless cells were primed by LPS56, a well-known modulator of macrophage differenti-
ation57. While studies of mature phagocytes in serum-free environment is relevant as a model for inflammatory 
response in tissue/joints, whole blood suspension cultures used by us, suit better to study the effects of uric acid 
in the circulation. As NLPR3 has intracellular localization58, its activation with subsequent IL-1ß production 
requires phagocytic uptake of MSU crystals56. Indeed, addition of Cytochalasin D blocks MSU-crystal phagocy-
tosis and abolish activation of NLPR3 inflammasome and IL-1β release56. The weak IL-1ß upregulation in our 
experiments could be attributed to differences in the efficiency of phagocytosis and/or/ density of cell surface 
receptors between enriched cultures of mature phagocytes and peripheral blood cells. Another possible expla-
nation is the presence of plasma in our cultures which is known to contain elements that can non-specifically 
antagonize pro-inflammatory responses to crystallized uric acid, such as CD-4459 and apolipoprotein B60. At the 
same time, MSU-crystals in our model induced significant increase in the production of other pro-inflammatory 
cytokines, such as TNF-a and IL-8, confirming that activation of pro-inflammatory pathways has taken place. A 
more feasible explanation is therefore sub-optimal timing for IL-1ß assessment.
UA has been shown to reduce ROS intracellularly in cultured fibroblast by uptake through GLUT9 (SLC2A)61. 
The results from our UA uptake experiment indicated that UA is indeed internalized into blood cells. However, 
the type of cells responsible for the uptake remains to be determined. Rough separation of blood suspension 4 h 
after incubation with 14C-UA into erythrocytes and buffy coat fractions showed that the majority of cell-associated 
radioactivity was present in the erythrocyte fraction (data not shown). Whether white blood cells contribute to 
14C-UA internalization remains to be determined.
The cell-associated radioactivity detected at the first time point (5.2% and 2.5% for males and females respec-
tively) indicates a very rapid initial uptake of UA. When the uptake experiments were conducted on ice almost 
no cell-associated radioactivity was detected (1.3%) and no changes in dynamics observed during 4 h (data not 
shown). This suggests that the uptake of UA by blood cells is not free diffusion across cell membrane the process 
that would not be significantly hindered by low temperature. Furthermore, the rate of UA uptake suggests that 
fluid phase pinocytosis is unlikely to be the mechanism behind. Receptor-mediated endocytosis is also unlikely to 
be involved since no endocytic receptor for UA has been described in humans so far. However, receptor-mediated 
endocytosis of UA was demonstrated in yeast62. Therefore, the most probable mechanism for UA uptake in blood 
cells is via transmembrane transporters. The possible candidates of UA transporters are GLUT9, URAT1, OAT10 
and OAT4 among others31. However, addition of inhibitors probenecid and tranilast did not affect uptake of UA 
(data not shown). Probenecid and tranilast are considered by many to be inhibitors for all the UA transporters 
mentioned above63. However, some authors define probenicid solely as URAT1 inhibitor. Nevertheless, our data 
indicate that neither GLUT9, URAT1, OAT10 nor OAT4 are involved in UA uptake by blood cells, while it has 
been previously reported that probenecid retards the uptake of UA, at least in human erythrocytes64. It should be 
noted that with renal tubular epithelial cells as exception, urate uptake mechanisms are not well described. Since 
only overall UA uptake but not rate of uptake were higher in male group the observed difference in UA uptake 
between sexes may be due to typically higher erythrocyte numbers in male compared to female subjects.
This study has several limitations. We were not able to measure UA in the cultures because we used 
anti-coagulated blood and the final concentration of UA in cultures is therefore unknown. The use of only male 
donors in the experiments studying inflammatory responses weakens the external validity of the study. The 
number of cytokines and chemokines we measured was limited due to financial restrains. The response to MSU 
crystals in our study was also somewhat weaker than described by others. This may be due to differences in exper-
imental design, such as longer MSU crystals incubation times or the production of smaller or otherwise qualita-
tively different crystals in other studies65. Based on earlier kinetic experiments performed in similar whole blood 
models with LPS as stimulant we chose to incubate our cultures for four hours prior to cytokine analysis32,66. 
However, it might be that longer incubation is needed when using MSU crystals as stimulant. No measurements 
of oxidation products or oxidative burst were conducted in our experiments, and consequently, it is not possible 
to exclude that UA may have an effect on ROS-production that we did not detect. The timing for sample collection 
might not be optimal for all the cytokines we wanted to study. Because earlier kinetic experiments performed in 
similar whole blood models indicated that two hour incubation was probably too short to observe the full effect 
on MCP-1 and IL-8 release32,66, we extended the study with sampling also at four hour time point. Another limi-
tation with the whole blood model for studying chemokines is the presence of Duffy-receptor on red blood cells, 
which is known to scavenge MCP-1 and IL-8 from plasma33,67 and mask the effect of UA on production of these 
chemokines. At the same time scavenging would doubtfully mask changes in cytokine gene expression, which in 
our experiments were consistent with ELISA results. In addition, the relatively low number of study participants, 
the use of young, healthy and mainly male donors are all important limitations.
The strength of this study is the use of freshly drawn human whole blood in an ex vivo inflammation 
model. Exposure of whole blood to high concentrations of UA allows studying the uptake and responses to this 
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metabolite in a setting that is more similar to the situation in the circulation than what can be achieved by using 
cultures of purified blood cell types or human cell lines. Results from the hematological differential counting and 
assessment of metabolic parameters indicate that cell viability and metabolism were not considerably affected by 
incubation of blood for up to four hours ex vivo. Humans have higher SUA levels and different purine metabolism 
than most other mammals, including the typical laboratory animals - rats and mice30. The external validity of the 
study is therefore also superior compared to studies in animal models.
Conclusion
Crystallized, but not soluble, UA elicits production of pro-inflammatory cytokines TNF-α and IL-1ß, chemokines 
MCP-1 and Il-8, and IL-RA in short-term cultures of whole blood from healthy young men. Soluble UA was taken 
up by blood cells but did not seem to potentiate or reduce LPS-induced release of cytokines. The subgroup of 
blood cell(s) responsible for UA internalization and the mechanism behind need further investigation.
Methods
ethics approval and consent to participate. The study has been approved by the Regional Committee 
for Medical and Health Research Ethics (2014/73). All the study participants signed the informed consent form 
prior to participation. The biological material in the study was used without keeping any linked information on 
the identity or health status of the donors. All methods were performed in accordance with the relevant guidelines 
and regulations.
Materials. Uric acid (HPLC quality) (Sigma-Aldrich), Lipopolysaccharide (LPS) from E. coli 026:B6 
(Sigma-Aldrich), EDTA 1% (w/v) in PBS without Ca2+ and Mg2+ (Versen Biochrome, Germany), RPMI-1640 
cell culture medium (Sigma-Aldrich), Tissue solubilizer “Solvable” (PerkinElmer), “Ultima Gold” scintillation 
cocktail (PerkinElmer), 14C labelled uric acid (50 mCi/mmol) (Hartmann Analytic GmbH). Probenecid and tra-
nilast were purchased from Sigma-Aldrich.
preparation of solutions. A 4 mM UA stock solution was prepared by dissolving UA powder in 4.06 mM 
NaOH and pH was adjusted to 8.5 to obtain long-term stable stock solution. The 4 mM UA stock solution was fur-
ther diluted with 1.8% NaCl to produce 2 mM UA/0.9% NaCl stock solution. All solutions were filtered through 
a 0.2 µm syringe filter (Acrodisc, Pall corporation, NY, USA) before use. MSU crystals were prepared by addition 
of NaCl to 4 mM UA stock solution to 0.9%, followed by cooking at 100 °C for 6 h and allowing to precipitate at 
room temperature under sterile conditions for 5–7 days. The crystal formation was checked microscopically. The 
crystals were typically 5–25 µm long. LPS was reconstituted in 0.9% NaCl to 500 ng/ml working solution.
Cytokine production in whole blood suspension culture. A human whole blood suspension model 
was used as earlier described by others68. Healthy male study participants, aged 18–40 years, were recruited from 
the university, hospital staff members and students. Only males were invited to avoid introducing heterogeneity 
in the donors from cyclical changes of estrogens during menstrual cycle known to affect immune response and 
cytokines production69–71. Exclusion criteria were self-reported concurrent use of medications or any chronic 
or acute illness. Blood samples were slowly aspirated from the antecubital vein into a 20 ml polypropylene (BD 
Falcon) syringe, with a 19-gauge needle and anticoagulated with Dalteparin sodium (Fragmin, Pfizer) 10 IE/ml 
blood. Aliquots of blood were immediately transferred to 50 ml polypropylene tubes to establish 3 ml blood cul-
tures. UA stock solutions were added to achieve final concentrations of 200 µM or 500 µM on top of the donors’ 
level to represent moderate and high level of SUA72. MSU crystals were added to one of the cultures to a final 
concentration of 0.78 mg/ml. The volumes of uric acid in solution and crystal suspension added to whole blood 
cultures, were the same and comprised 1% of total culture volume. The tubes were capped, inverted gently and 
incubated in a rotary shaker incubator at 37 °C for 1 h, followed by addition of 30 µl of LPS working solution to a 
final concentration of 5 ng/ml or vehicle. At 2 h the tubes were gently inverted to mix and an aliquot of 2 ml was 
transferred to a Tempus tube (Applied Biosystems) mixed and kept frozen at −20 °C. The remaining 1 ml of blood 
cultures continued incubation in a rotary shaker incubator at 37 °C for additional 2 h, followed by centrifugation 
at 2000g for 10 min. Plasma was then collected and kept frozen at −70 °C until further analyses.
Quantitative pCR. Total RNA was extracted using the PerfectPure RNA Blood Kit (5′Prime) or RNeasy 
Mini Kit (Qiagen) according to the manufactures instructions. Isolated RNA was quantified by NanoDrop 1000 
Spectrophotometer (Thermo Scientific). Isolated RNA samples were diluted to final concentration 25 ng/µl and 
cDNA synthesis was conducted with High CapacitycDNA kit (Applied Biosystems) using 500 ng mRNA in a 
total reaction volume of 20 µL. cDNA synthesis were performed with and without RT enzyme to generate cDNA 
and RT-free negative controls. Quantitative PCR (qPCR) was performed using gene-specific primers (Table 1). 
Fast SYBR© Green master mix (Applied Biosystems) or Fast start Essential DNA green Master (Roche), primers 
and 2 µL of 1:4 diluted cDNA were used in a total of 10 µL reaction volume. cDNA was amplified in duplicates 
in Roche Light Cycler 96 (Roche). Thermal cycling settings were pre-denaturing at 95 °C for 10 min, followed by 
40 cycles of 95 °C for 10 s, 60 °C for 10 s and 72 °C for 10 s. A negative control and RT-free negative control were 
included in every assay. The following primer pairs were used 5′ to 3′
The PCR efficiency for all primer sets was determined by performing a serial dilution of pooled cDNA from all 
individuals. Melting curves were assessed to control for non-specific amplification. RPL-13A was used as a refer-
ence gene for normalization of cytokine gene expression (∆Ct) with adjustment for efficiency of amplification73.
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Measurements of cytokines in culture plasma. Luminex® Assay Human Premixed Multi-Analyte Kit 
(R&D systems) was used for simultaneous measurement of IL-1ß, IL-1RA, TNF-α, IL-8, MCP-1 and ICAM-1 
(negative control). The plasma samples were diluted with PBS prior to analysis and analyzed in duplicates accord-
ing to the manufactures instructions. The chemiluminescense was read on a VERSAmax Absorbance Microplate 
Reader (Molecular Devices). Final plasma concentrations were calculated using the Bioplex software supplied by 
the manufacturer. The standard curve was constructed using a 4-parameter logistic function.
Differential counting and metabolic analyses. Aliquots of blood were pipetted into 15 ml polypro-
pylene centrifugation tubes (BD falcon) containing either vehicle (0.9% NaCl), uric acid (200 µM and 500 µM), 
MSU crystals (0.78 mg/ml) or LPS (5 ng/ml) to a total volume of 2 ml. The tubes were inverted ten times and incu-
bated with closed caps at 37 °C in a shaker incubator. At baseline and following two or four hour incubation, the 
experiments were stopped by placing the tubes on ice. A 1000 µl of blood was pipetted to standard EDTA tubes 
for hematological differential cell counting performed at Clinical Chemistry Department, University Hospital of 
North Norway. Lactate, glucose, pH, pO2, pCO2, Na+, K+, Cl− and Ca2+ concentrations were analyzed with an 
ABL 800 blood gas analyzer (Bergmann diagnostika).
Measurement of UA uptake by blood cells. Blood from six healthy volunteers (three males and three 
females) was collected as described above. Blood was mixed 1:1 with RPMI-1640 cell culture medium containing 
1 µM 14C-UA and 1000 µM non-labelled UA. A total volume of 1790 µl of the mixture was pipetted into six well cell 
culture plates (BD Falcon) and incubated at 37 °C 5% CO2 on a shaker board. Incubation was terminated at 0, 0.5, 
1, 2 and 4 h by transferring the cell suspensions to 2 ml microcentrifuge tubes (Eppendorf) and centrifuged at 2000 
G for 10 min at 5 °C. Supernatants and cellular fractions were separated and hydrolyzed by incubation with tissue 
solubilizer “Solvable” at 55 °C for 3 hours according to manufacturers’ instructions. To the hydrolyzed cellular 
fractions, 50 µl of 0.2 M EDTA and 500 µl of 30% hydrogen peroxide were added and the mixtures were incubated 
at room temperature for 30 min, and then at 55 °C for 60 min in order to decolorize the samples. After cooling 
down, both fraction types were mixed with 17.7 ml “Ultima Gold” scintillation cocktail. Radioactivity (d.p.m.) was 
measured in a Packard Liquid Scintillation Counter. The extent of UA degradation was determined by counting 
radioactivity after addition to cell culture supernatants of ZnCl2 that precipitates only non-degraded UA.
Inhibition experiments. Incubation on ice was performed in order to differentiate between free diffusion 
across cell membrane where the dependence on temperature is negligible74 and endocytic uptake and facilitated 
transport (membrane transporters) where effect of temperature lowering is significant74,75. Addition of probene-
cid (final concentration 1 mM) and tranilast (final concentration 100 µM) to blood culture was used to analyze 
whether GLUT9, URAT1, OAT10 and OAT4 transporters were responsible for uric acid uptake63.
statistical analysis. Prism 6 and 7 (Graph Pad software inc.) were used to make figures and conduct sta-
tistical analyses. A paired t-test was used when two groups were compared with each other. A repeated measures 
ANOVA with a Geissner-Greenhouse correction for not assuming sphericity was used to compute P values for 
the main effects in the cytokine experiments. Provided significant differences were observed on an alpha level 
of ≤ 0.05 in the repeated measures ANOVA, Dunnett’s multiple comparison test was conducted. P-values were 
adjusted for multiple comparisons. For UA uptake studies, the dynamics of blood cells’ 14C-UA-associated radi-
oactivity was analyzed using non-linear regression. The model that best described the radioactivity uptake data, 
(one phase association model), was selected using the Akaike’s Information Criterion (AIC)76. The differences 
between sex groups were determined by comparing best-fit values of parameters using F-test.
Data Availability
The data that support the findings of this study are available from UiT - The Arctic university of Tromsø - but 
restrictions apply to the availability of these data, which were used under license for the current study, and so are 
not publicly available. Data are, however, available from the authors upon reasonable request and with permission 
of UiT - The Arctic university of Norway and the Regional committee for medical and health research ethics.
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